Dayvigo 5 Mg (Lemborexant)

Product Overview

Dayvigo 5 mg is a prescription medication formulated to address chronic insomnia, a condition characterized by difficulty falling asleep, staying asleep, or obtaining restorative sleep. The active ingredient, lemborexant, belongs to a class of drugs known as dual orexin receptor antagonists (DORAs), which work by modulating the brain’s wake‑promoting pathways. Manufactured by Eisai Pharmaceuticals India Pvt. Ltd, Dayvigo is supplied in blister packs containing 14 tablets, each strength of 5 mg. The product is also available in larger pack sizes of 28, 56, and 84 tablets, offering patients a convenient option for long‑term therapy. This section provides a comprehensive look at the medication, its clinical purpose, and what patients can expect when using Dayvigo as part of a medically supervised treatment plan.

What is Dayvigo 5 mg (Lemborexant)

Dayvigo, known generically as lemborexant, is an FDA‑approved oral hypnotic indicated for the treatment of insomnia, specifically for adults who experience trouble with sleep onset or maintenance. Unlike traditional sedative‑hypnotics, lemborexant selectively blocks the orexin receptors that promote wakefulness, thereby facilitating a natural transition to sleep without the abrupt “hang‑over” effect seen with some other agents. The 5 mg dosage represents the recommended starting strength for most patients, with titration possible based on efficacy and tolerability. The medication is taken once nightly, at least 30 minutes before bedtime, and should be swallowed whole with a full glass of water.

Uses and Benefits

The primary use of Dayvigo is to improve sleep latency and total sleep time in patients with insomnia. Clinical trials have demonstrated that patients receiving lemborexant experienced a statistically significant increase in total sleep time and a reduction in sleep onset latency compared with placebo. Key benefits include:

• Faster sleep onset, helping individuals fall asleep more quickly.
• Improved sleep maintenance, reducing nighttime awakenings.
• Enhanced perceived sleep quality, leading to better daytime functioning.
• A low potential for next‑day residual sedation when taken at the recommended dose.
• Compatibility with cognitive‑behavioral therapy for insomnia (CBT‑I) as an adjunctive option.

These attributes make Dayvigo a valuable addition to a broader sleep‑management strategy that may also involve lifestyle modifications, sleep hygiene education, and behavioral interventions.

How It Works

Lemborexant acts as a selective antagonist at the orexin‑1 and orexin‑2 receptors, which are integral to the regulation of the sleep‑wake cycle. Orexin neuropeptides promote arousal; by blocking their activity, lemborexant reduces the brain’s wake‑promoting signals, allowing the natural sleep‑inducing mechanisms to dominate. This mechanism distinguishes DORAs from older classes of hypnotics that primarily rely on gamma‑aminobutyric acid (GABA) modulation. The result is a more physiologic approach to sleep induction that preserves the architecture of natural sleep stages, including slow‑wave and REM sleep, thereby supporting restorative rest.

Dosage Guidelines

Dayvigo is administered as a single oral dose of 5 mg taken once daily, preferably at the same time each night. The dosage may be adjusted by a healthcare professional based on individual response, comorbid conditions, or concomitant medications. Important dosing considerations include:

• Take the tablet on an empty stomach or with a light snack; food has not been shown to significantly affect absorption.
• Do not exceed the prescribed dose without medical supervision.
• If a dose is missed, skip it and resume the regular schedule the following night; do not double up.
• Patients with hepatic impairment may require a lower dose; consult a physician for guidance.
• Long‑term use should be reassessed periodically to determine continued need.
• Patients should not take more than one tablet per night and should avoid use in patients with severe untreated sleep apnea unless a clinician advises otherwise.

Always follow the prescribing information and discuss any dosage changes with a qualified healthcare provider.

Side Effects

Like all medications, Dayvigo can cause adverse effects. Most side effects are mild to moderate and often resolve with continued use. Commonly reported events include:

• Headache
• Dry mouth
• Somnolence (daytime drowsiness)
• Dizziness
• Abnormal dreams

Less frequent but clinically important adverse reactions may comprise:

• Complex sleep behaviors such as sleep‑walking, sleep‑driving, or sleep‑eating.
• Severe allergic reactions (rash, itching, swelling).
• Depression or worsening of mood disorders.
• Next‑day residual sedation in some individuals.

Patients should contact their physician promptly if they experience any of these symptoms, especially if they interfere with daily activities or persist over time. Long‑term safety data are still being collected; periodic assessments are recommended.

Warnings and Precautions

Before initiating Dayvigo therapy, healthcare providers should assess for potential contraindications and risk factors. Key warnings include:

• Complex sleep behaviors: The FDA has issued a boxed warning for rare but serious activities performed during decreased consciousness, such as sleep‑driving.
• Alcohol and CNS depressants: Concomitant use may increase the risk of additive sedation.
• Pregnancy and lactation: The medication should only be used if the benefits outweigh potential risks; discuss with a clinician.
• Hepatic impairment: Dose adjustments may be necessary; monitor liver function tests.
• Drug interactions: Certain medications, including ketoconazole and rifampin, can affect lemborexant levels.
• Use in elderly patients: Start at the lowest effective dose and monitor for increased sensitivity to side effects such as dizziness or next‑day drowsiness.

Patients are advised to store the medication at room temperature, away from moisture and heat, and to keep it out of reach of children. A comprehensive review of medical history with a prescribing clinician is essential before starting treatment. For additional guidance, refer to the FDA website and MedlinePlus.

Frequently Asked Questions

1. What is the recommended starting dose of Dayvigo?

The standard initial dose is 5 mg taken once nightly. Some patients may require dose adjustment based on tolerability and clinical response, but any changes should be made under medical supervision.

2. How long does it take for Dayvigo to improve sleep?

Clinical studies indicate that patients may notice improvements in sleep onset and total sleep time within the first week of treatment, with maximal benefits often observed after two to four weeks of consistent use.

3. Can Dayvigo be taken with other sleep medications?

Combining Dayvigo with other hypnotic agents is generally not recommended unless specifically directed by a healthcare professional, due to the potential for additive sedative effects.

4. Is Dayvigo safe for older adults?

Older adults can use Dayvigo, but clinicians should start at the lowest effective dose and monitor for increased sensitivity to side effects such as dizziness or next‑day drowsiness. Dose adjustments may be needed in patients with reduced hepatic function.

5. Where can I find more detailed prescribing information?

For full prescribing details, including contraindications and drug interaction data, refer to the official FDA label or consult a pharmacist. Additional resources are available at the FDA website and MedlinePlus.

Related Products

• Aricep (Donepezil)
• Aricep 5 mg (Donepezil)
• Aricep 10 mg (Donepezil)
• Aricep 23 mg (Donepezil)
• Eprisan (Eperisone)
• Eprisan 50 mg (Eperisone)
• Eprisan 150 mg (Eperisone)
• Lenvima Tablet (Lenvatinib)
• Lenvima 4 Mg (Lenvatinib)
• Lenvima 10 mg (Lenvatinib)
• Dayvigo 10 Mg (Lemborexant)
• Dayvigo (Lemborexant)